27 June 2018
The first accelerated approval for a tumor-agnostic drug was granted by the FDA in May 2017, enabling patients with any locally advanced or metastatic solid tumor expressing particular biomarkers for...
8 May 2018
The FDA has granted priority review for Merck’s Keytruda (pembrolizumab) + Alimta (pemetrexed injection) + platinum-based chemotherapy combination as a first-line treatment for patients with metastatic non-squamous, non-small cell lung...
23 April 2018
Follow-up results from Phase IIb clinical trials demonstrating the efficacy of Synthetic Biologics’ ribaxamase (SYN-004) in protecting the gut microbiome in patients receiving IV ceftriaxone were presented at the 2018...
1 March 2018
The number of first approvals for biosimilars in the US, Japan, or EU has increased significantly in the past two years, breaking the stagnation of the three years prior, with...
30 January 2018
Takeda and its partner, Zinfandel, have announced that the investigation of Actos (pioglitazone) in the global Phase III TOMMORROW trial, one of the largest studies ever to be executed in...
12 January 2018
Pavan Kottamasu, GlobalData Healthcare & Pharmaceutical Analyst Jeffrey Leiden, M.D., Ph.D., Chairman, President, and CEO of Vertex Pharmaceuticals, took the stage on Day 1 of the 2018 J.P. Morgan (JPM)...
1 December 2017
The number of tech transfer deals has been increasing for the last 10 years, with the exception of 2012, although the sum of the deal values, year on year has...
16 November 2017
In an effort to seek a novel business model, there has been a significant focus on pharma’s strategies to go “beyond the pill”, creating services and solutions that are complementary...
30 October 2017
Design ankyrin repeat proteins (DARPins) have the potential to be a major disruptive technology in biologics-based therapy.
17 October 2017
Scientists at the University of California, Berkeley, have engineered a new way to deliver CRISPR gene-editing technology inside cells, and have demonstrated in mice that it can repair the faulty...